Pediatrix Medical Group, Inc. filings document the public-company disclosures of a Florida physician-services operator focused on obstetrics, maternal-fetal medicine, neonatology and pediatric subspecialty care. Recent Form 8-K reports furnish operating results, including net revenue, earnings measures, same-unit revenue drivers, reimbursement factors, patient volume trends and hospital-based practice activity.
Proxy and governance filings cover director elections, shareholder voting results, executive compensation, pay-versus-performance data and the Pediatrix Medical Group, Inc. Second Amended and Restated 2008 Incentive Compensation Plan. Other material-event reports address board appointments, Regulation FD disclosures and common-stock repurchase authorizations.
Pediatrix Medical Group, Inc. (MD) received a Rule 144 notice from officer Mary Ann E. Moore covering an intended sale of 21,335 shares of common stock through Merrill Lynch on the NYSE. The filing states an aggregate market value of $572,619.71 for these shares and notes 81,253,271 shares outstanding as of September 11, 2026. The shares relate to multiple vested stock awards and follow a prior sale of 9,260 shares in the last three months.
Pediatrix Medical Group, Inc. (MD) officer Mary Ann E. Moore filed a Rule 144 notice to sell 9,260 shares of common stock through Merrill Lynch on the NYSE, with an indicated aggregate market value of $246,365.53. Shares outstanding were 81,253,271 as of the planned sale, a baseline figure, not the amount being sold.
Pediatrix Medical Group, Inc. (MD) director Laura A. Linynsky reported a disposition to the issuer of 6,000 shares of Common Stock on September 10, 2026, at $26.82 per share. After this transaction, she directly holds 33,900 shares. No Rule 10b5-1 trading plan is reported for this transaction.
Pediatrix Medical Group, Inc. (MD) received a Form 144 notice indicating that director Laura Linynsky plans a Rule 144 sale of up to 6,000 shares of common stock. The shares were acquired through stock plan activity, and Merrill Lynch is listed as the broker for the proposed transaction.
Pediatrix Medical Group, Inc. (MD) is the subject of a Schedule 13G filing by Vanguard Portfolio Management regarding its beneficial ownership of the company’s common stock. The filing states that it is being submitted solely to correct the issuer CIK previously reported and that no change in beneficial ownership is being reported.
Vanguard Portfolio Management reports 6,278,234 shares beneficially owned, representing 7.55% of the common stock. It has sole power to vote or direct the vote over 124,108 shares and sole power to dispose or direct the disposition of 6,278,234 shares, with no shared voting or dispositive power. The holdings include securities held by various Vanguard-affiliated entities and Vanguard funds over which it or its affiliates exercise dispositive and/or voting power.
Pediatrix Medical Group, Inc. (MD) is reported as having 4,283,221 shares of its common stock beneficially owned by Vanguard Capital Management on a Schedule 13G, representing 5.15% of the class as of March 31, 2026.
Vanguard Capital Management has sole voting power over 626,900 shares and sole dispositive power over 4,283,221 shares, with no shared voting or dispositive power. The submission states it is being filed solely to correct the issuer CIK from a prior report and that no change in beneficial ownership is being reported.
Pediatrix Medical Group, Inc. (MD) received an amended Schedule 13G/A from The Vanguard Group reporting that it now holds 0 shares of Pediatrix common stock, representing 0% of the class, with no voting or dispositive power.
The Vanguard Group explains that, following an internal realignment on January 12, 2026 and in reliance on SEC Release No. 34-39538, certain subsidiaries or business divisions that previously were aggregated with The Vanguard Group will now report their beneficial ownership separately. The amendment here is stated to be filed solely to correct the issuer’s CIK in a prior amendment, and it does not report any change in beneficial ownership.
Pediatrix Medical Group, Inc. (MD) director Sylvia Jean Young reported a disposition of common stock to the issuer. On 2026-08-14, she disposed of 18,500 shares at a weighted average price of $26.62 per share, in multiple transactions executed between $26.51 and $26.80. Following this issuer disposition, she directly holds 29,786 shares of Pediatrix Medical Group common stock.
McEachin Thomas reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Thomas McEachin received a grant of 472 restricted shares of common stock on August 12, 2026 at a reference value of $26.50 per share under the Second Amended and Restated 2008 Incentive Compensation Plan. His directly held shares increased to 7,668, and he also reports 66,073 shares held indirectly through the Thomas A. McEachin Living Trust, with he and his spouse as trustees and beneficiaries. The restricted shares will vest on May 7, 2027.